Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A Bayesian dosing method for carboplatin given by continuous infusion for 120 h

P Guillet1, S Monjanel, A Nicoara

  • 1Service d'oncologie médicale, CHU Timone Adultes, Marseille, France.

Cancer Chemotherapy and Pharmacology
|January 1, 1997
PubMed
Summary

A new Bayesian dosing method for carboplatin (CBDCA) involves continuous infusion over 120 hours. This pharmacokinetic approach allows for precise, individualized dosing, potentially increasing the median dose by 20% with acceptable tolerance.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dietary lipid droplet size and phospholipids modulate lipid digestion and absorption in early life nutrition, an in vitro study.

Food chemistry·2026
Same author

Magnetic imaging under high pressure with a spin-based quantum sensor integrated in a van der Waals heterostructure.

Nature communications·2025
Same author

Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

COREGO: drug-drug interaction analysis on the efficacy and safety of regorafenib in patients with a sarcoma: pooled analysis of the data from the REGOSARC and REGOBONE trials.

ESMO open·2025
Same author

Proof of concept and design of an externally controlled trial for patients with gastro-enteropancreatic neuroendocrine carcinomas based on the randomized phase II BEVANEC trial.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Nuclear Magnetic Resonance with a Levitating Microparticle.

Physical review letters·2024

Area of Science:

  • Oncology
  • Pharmacokinetics
  • Clinical Pharmacology

Background:

  • Carboplatin (CBDCA), a cisplatin analog, has variable pharmacokinetics requiring dose individualization.
  • Standard short-term infusion schedules are associated with significant side effects.
  • Existing dosing formulas often rely on renal function estimation, which can be imprecise.

Purpose of the Study:

  • To introduce and evaluate a novel pharmacokinetic dosing method for carboplatin using Bayesian estimation.
  • To assess the feasibility and safety of a 120-hour continuous infusion schedule for carboplatin administration.
  • To determine if this new method allows for more precise and potentially higher carboplatin dosing.

Main Methods:

  • Population pharmacokinetic parameters for carboplatin were determined in 21 patients.

Related Experiment Videos

  • A Bayesian method was employed for individualized carboplatin dosing based on plasma concentration measurements.
  • The new protocol was evaluated in 36 patients (60 courses) using continuous infusion over 120 hours.

    • Main Results:

    • The Bayesian dosing method enabled precise individualization of carboplatin doses within 24 hours of infusion.
    • Measured end-infusion concentrations closely matched theoretical targets (e.g., 1.72 mg/l vs. 1.8 mg/l target).
    • The median administered carboplatin dose was 20% higher (484 mg/m²) compared to the standard dose (400 mg/m²) with acceptable tolerance.

    Conclusions:

    • The proposed Bayesian pharmacokinetic dosing method for carboplatin is precise, unbiased, and practical for clinical use.
    • This 120-hour continuous infusion schedule offers acceptable tolerance and allows for a higher median dose.
    • Further studies are needed to confirm if this new administration scheme provides equal or superior efficacy compared to classic protocols.